40.45
+3.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xenon Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Xenon Pharmaceuticals is based in Burnaby and is incorporated in British Columbia, Canada. Its shares trade on Nasdaq under the ticker XENE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $7.5m and a net loss of $345.9m. At that date it held total assets of $633.2m and shareholders' equity of $581.8m.
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
Our goal is to build a fully-integrated and profitable biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics to treat a range of neurological and psychiatric disorders.
Azetukalner, a novel, potent Kv7 potassium channel opener, represents the most advanced, clinically-validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications, including two in epilepsy – focal onset seizures, or FOS, and primary generalized tonic-clonic seizures, or PGTCS, – as well as neuropsychiatric disorders, including MDD or BPD.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Oct 2014
- Employees
- 358
- Website
- xenon-pharma.com ↗
- Head office
- 200 - 3650 GILMORE WAY, BURNABY
- Incorporated in
- A1
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Dawn SvoronosLead Independent Chairman of the Board$504,929
- Mr. Ian MortimerPresident, Chief Executive Officer, Interim Chief Financial Officer, Director, since 2013$9.8m
- Mr. Darren ClineChief Commercial Officer
- Dr. Christopher KenneyChief Medical Officer$4.2m
- Ms. Andrea DifabioChief Legal Officer, Corporate Secretary$4.1m
- Dr. Gillian CannonIndependent Director$462,232
- Mr. Steven GannonIndependent Director$478,976
- Dr. Elizabeth GarofaloIndependent Director$464,390
- Mr. Justin GoverIndependent Director$468,634
- Mr. Patrick MachadoIndependent Director$476,596
- Dr. Gary PatouIndependent Director$471,084
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xenon Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. One of its notable strengths is its strong research and development capabilities. Xenon Pharmaceuticals Inc invests heavily in research and has a team of highly skilled scientists dedicated to discovering novel drug candidates. This expertise allows the company to develop innovative drugs that address unmet medical needs, giving them a competitive advantage in the market. Another strength of Xenon Pharmaceuticals Inc is its extensive intellectual property portfolio. The company has a robust patent portfolio that protects its innovative drug candidates and technologies. This helps secure its position in the market and prevents competitors from easily replicating its products or processes. Additionally, Xenon Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies. These partnerships provide the company with access to additional resources, expertise, and market reach, further strengthening its position in the industry. Lastly, Xenon Pharmaceuticals Inc has a strong financial position. The company has consistently generated revenue through collaborations and partnerships, enabling it to fund its research and development activities without relying solely on external financing.
Weaknesses
- Despite its strengths, Xenon Pharmaceuticals Inc also faces certain weaknesses that may pose challenges to its growth and profitability. One significant weakness is its heavy reliance on a limited number of drug candidates in its pipeline. The success of the company heavily depends on the approval and commercial success of these drugs. Any setbacks or failures in clinical trials or regulatory processes could have a significant impact on Xenon Pharmaceuticals Inc's financial performance. Another weakness is the inherent risk associated with drug development. The pharmaceutical industry is highly regulated, and the development of new drugs involves considerable time and cost. There is always a risk that the drugs in Xenon Pharmaceuticals Inc's pipeline may not meet the necessary safety and efficacy standards required for regulatory approval, resulting in wasted resources and lost opportunities. Additionally, Xenon Pharmaceuticals Inc has a relatively small market share compared to some of its larger competitors. This may limit its ability to negotiate favorable terms with distributors or access to global markets, hindering its growth potential. Lastly, there is a constant need for ongoing investment in research and development. This puts pressure on Xenon Pharmaceuticals Inc to continuously allocate resources and capital to maintain its competitive edge in an ever-evolving industry.
Opportunities
- Xenon Pharmaceuticals Inc operates in a continually evolving pharmaceutical industry, presenting numerous opportunities for growth and expansion. One opportunity lies in the increasing global demand for innovative therapeutics. As healthcare systems advance and diseases become more complex, there is a growing need for targeted and personalized treatments. Xenon Pharmaceuticals Inc's focus on developing novel drugs positions it well to capitalize on this market demand. Another opportunity is the potential for strategic collaborations and licensing agreements. Xenon Pharmaceuticals Inc can leverage its expertise and intellectual property to negotiate partnerships with larger pharmaceutical companies. Such collaborations could provide access to additional resources, distribution networks, and accelerate the commercialization of its drug candidates. Furthermore, advancements in genetic research and precision medicine present opportunities for Xenon Pharmaceuticals Inc to develop targeted therapies based on individual genetic profiles. This personalized medicine approach could revolutionize treatment options and potentially lead to partnerships with genetic testing companies or healthcare providers. Lastly, expansion into emerging markets provides an opportunity for Xenon Pharmaceuticals Inc to tap into untapped patient populations and diversify its revenue streams. By adapting its products and strategies to suit the specific needs and regulations of these markets, the company can access new customer bases and increase its global presence.
Threats
- Alongside opportunities, Xenon Pharmaceuticals Inc faces certain threats that could impact its operations and growth. One primary threat is the intense competition within the pharmaceutical industry. The market is populated with numerous established pharmaceutical companies, as well as emerging biotechnology firms. This competitive landscape increases the challenges of gaining market share and differentiating Xenon Pharmaceuticals Inc's products from those of its competitors. Another threat comes from the ever-changing regulatory environment. Stringent regulations are in place to ensure the safety and efficacy of drugs, but compliance with these regulations adds complexity and cost to the drug development process. Any changes in regulations or delays in regulatory approvals can significantly impact Xenon Pharmaceuticals Inc's timelines and profitability. Additionally, the rapidly evolving technological landscape poses a threat. Advances in technology, such as gene-editing techniques or artificial intelligence-driven drug discovery, may disrupt traditional drug development approaches. Xenon Pharmaceuticals Inc needs to stay at the forefront of technological advancements to remain competitive and avoid being left behind. Lastly, economic factors and healthcare reforms can also pose threats. Changes in government policies, healthcare reimbursement systems, or economic downturns can adversely affect pharmaceutical companies' revenues and profitability. Xenon Pharmaceuticals Inc must carefully monitor and adapt to any such changes to mitigate potential risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.